Vardarli, I., Tan, S., Brandenburg, T. N., Weidemann, F., Görges, R., Herrmann, K., & Führer, D. (2024). Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: A meta-analysis of randomized controlled trials. The journal of clinical endocrinology & metabolism, 109(4), . https://doi.org/10.1210/clinem/dgad670
Chicago Style (17th ed.) CitationVardarli, Irfan, Susanne Tan, Tim Niclas Brandenburg, Frank Weidemann, Rainer Görges, Ken Herrmann, and Dagmar Führer. "Risk and Incidence of Endocrine Immune-related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-analysis of Randomized Controlled Trials." The Journal of Clinical Endocrinology & Metabolism 109, no. 4 (2024). https://doi.org/10.1210/clinem/dgad670.
MLA (9th ed.) CitationVardarli, Irfan, et al. "Risk and Incidence of Endocrine Immune-related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-analysis of Randomized Controlled Trials." The Journal of Clinical Endocrinology & Metabolism, vol. 109, no. 4, 2024, https://doi.org/10.1210/clinem/dgad670.